Total body hyperthermia in combination with etoposide and melphalan in a child with acute myelomonocytic leukemia.

Abstract

In vitro and clinical studies have shown antineoplastic effects of hyperthermia alone and in combination with other treatment modalities. Synergistic cytotoxic effects of chemotherapy and hyperthermia have been demonstrated on leukemic cell clones in vitro. It seems that hyperthermia is effective in overcoming chemotherapy resistance. Several groups treated solid tumors by using total body hyperthermia (TBHT). However, only a few studies have been reported investigating the clinical effects of TBHT in myeloproliferative disorders. We report the case of a 7-year-old boy with myelomonocytic leukemia treated with TBHT (2 hours, 42 degrees C) combined with etoposide (600 mg/m2), melphalan (30 mg/m2) and hyperglycemia (200-300 mg/dl). Within 24 hours after TBHT, the leukemic cells decreased after TBHT from 53,000/microliters to zero. Skin leukemic infiltrates, resistant to conventional treatment, also responded well. Although our patient relapsed 34 days after TBHT, these results indicate that TBHT in combination with cytotoxic treatment may be a useful treatment modality in refractory leukemia.

• Authors: R Wessalowski, U Willnow, H Jürgens, H Dehnen, U Göbel
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 22 Issue 1 Pg. 61-5 ( 1994) ISSN: 0098-1532 [Print] United States
• PMID: 8232083 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Etoposide
• Glucose
• Melphalan

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Child
• Combined Modality Therapy
• Etoposide (administration & dosage)
• Glucose (administration & dosage)
• Humans
• Hyperthermia, Induced (methods)
• Leukemia, Myelomonocytic, Acute (drug therapy, therapy)
• Male
• Melphalan (administration & dosage)
• Time Factors